Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

The Anti-Myeloma Efficacy of TAS0612, a Triple Inhibitor of RSK, AKT, and S6K, and Itssynergistic Combination with Venetoclax in Multiple Myeloma Irrespective of Cytogeneticabnormalities

Haruya Okamoto, Shinsuke Mizutani, Taku Tsukamoto, Yoko Katsuragawa-Taminishi, Yuka Kawaji-Kanayama, Kentaro Mizuhara, Ayako Muramatsu, Reiko Isa, Takahiro Fujino, Yuji Shimura, Koji Ichikawa, Junya Kuroda

Blood (2024) 144 (Supplement 1): 4178.

https://doi.org/10.1182/blood-2024-199695

Published: 2024

Journal Articles

The Activation Status of RSK2, but Not PDPK1 and AKT, Associates with the Prognosis of Diffuse Large B Cell Lymphoma

Akio Onishi, Aya Miyagawa-Hayashino, Kentaro Mizuhara, Ayako Muramatsu, Haruya Okamoto, Yuka Kawaji-Kanayama, Yoko Katsuragawa-Taminishi, Takahiro Fujino, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Eiichi Konishi, Junya Kuroda

Blood (2023) 142 (Supplement 1): 4390.

https://doi.org/10.1182/blood-2023-184365

Published: 2023

Journal Articles

TAS0612, a Triple Inhibitor for RSK, AKT, and S6K, Is a Promising Anti-Myeloma Agent Regardless of Types of Cytogenetic/Genetic Abnormality

Haruya Okamoto, Shinsuke Mizutani, Taku Tsukamoto, Yoko Katsuragawa-Taminishi, Reiko Isa, Kentaro Mizuhara, Ayako Muramatsu, Yuka Kawaji-Kanayama, Takahiro Fujino, Yuji Shimura, Junya Kuroda

Blood (2023) 142 (Supplement 1): 3313.

https://doi.org/10.1182/blood-2023-174157

Published: 2023

Journal Articles

The Universal Antitumor Activity of TAS0612, a Triple Inhibitor for RSK, AKT, and S6K, in B-Cell Lymphomas Regardless of Disease Subtype

Yoko Katsuragawa-Taminishi, Shinsuke Mizutani, Yuka Kawaji-Kanayama, Akio Onishi, Haruya Okamoto, Reiko Isa, Kentaro Mizuhara, Ayako Muramatsu, Takahiro Fujino, Taku Tsukamoto, Yuji Shimura, Masafumi Taniwaki, Aya Miyagawa-Hayashino, Eiichi Konishi, Junya Kuroda

Blood (2023) 142 (Supplement 1): 7135.

https://doi.org/10.1182/blood-2023-173485

Published: 2023

Journal Articles

Mir-106a-5p and Mir-146a-5p Delivered By Tumor-Derived Exosomes Promote the Induction of Myeloid-Derived Suppressor Cells from Normal Peripheral Blood Mononuclear Cells in Multiple Myeloma

Kentaro Mizuhara, Yuji Shimura, Taku Tsukamoto, Akinori Kanai, Saeko Kuwahara-Ota, Junko Yamaguchi, Ayako Muramatsu, Haruya Okamoto, Yoko Katsuragawa-Taminishi, Yuka Kawaji-Kanayama, Reiko Isa, Shinsuke Mizutani, Toshiya Inaba, Junya Kuroda

Blood (2022) 140 (Supplement 1): 9949–9950.

https://doi.org/10.1182/blood-2022-160408

Published: 2022

Journal Articles

Nutritional and Cytogenetic Assessment Predicts Favorable Response to Azacitidine Monotherapy for Myelodysplastic Syndromes

Haruya Okamoto, Yu Inoue, Akihiro Miyashita, Yuka Kawaji-Kanayama, Shotaro Chinen, Takahiro Fujino, Taku Tsukamoto, Yuji Shimura, Shinsuke Mizutani, Hiroto Kaneko, Saeko Kuwahara, Shin-ichi Fuchida, Daichi Nishiyama, Koichi Hirakawa, Junya Kuroda

Blood (2022) 140 (Supplement 1): 12321–12322.

https://doi.org/10.1182/blood-2022-157863

Published: 2022

Journal Articles

More Somatic Mutations Including Those in the Aid-Motif with High-Risk, Histologically Non-Transformed Follicular Lymphomas

Taku Tsukamoto, MD, Masakazu Nakano, PhD, Ryuichi Sato, Hiroko Adachi, Miki Kiyota, MD PhD, Satoru Yasukawa, MD PhD, Shotaro Tatekawa, MD, Yoshiaki Chinen, MD PhD, Hisao Nagoshi, MD PhD, Shinsuke Mizutani, MD PhD, Yuji Shimura, MD PhD, Mio Yamamoto-Sugitani, MD PhD, Tsutomu Kobayashi, MD PhD, Tomohiko Taki, MD PhD, Shigeo Horiike, MD PhD, Akio Yanagisawa, MD PhD, Masafumi Taniwaki, MD PhD, Kei Tashiro, MD PhD, Junya Kuroda, MD PhD

Blood (2016) 128 (22): 4116.

https://doi.org/10.1182/blood.V128.22.4116.4116

Published: 2016

Journal Articles

3-Phosphoinositide-Dependent Protein Kinase 1 (PDPK1) Is a Pivotal Cell Signaling Mediator in Multiple Myeloma

Yoshiaki Chinen, MD, Junya Kuroda, MD PhD, Yuji Shimura, MD PhD, Hisao Nagoshi, MD PhD, Miki Kiyota, MD PhD, Mio Yamamoto-Sugitani, MD PhD, Shinsuke Mizutani, MD, Natsumi Sakamoto, Masaki Ri, MD PhD, Eri Kawata, MD PhD, Tsutomu Kobayashi, MD PhD, Yosuke Matsumoto, MD PhD, Shigeo Horiike, MD PhD, Shinsuke Iida, Masafumi Taniwaki, MD PhD

Blood (2014) 124 (21): 4728.

https://doi.org/10.1182/blood.V124.21.4728.4728

Published: 2014

Journal Articles

Novel Fusion Transcripts PVT1-NSMCE2 and BF104016-NSMCE2 Resulting In Depletion Of NSMCE2 Protein In Acute Myeloid Leukemia Harboring 8q24 Amplicons

Yoshiaki Chinen, MD, Natsumi Sakamoto, Hisao Nagoshi, MD, PhD, Tomohiko Taki, MD, PhD, Satoru Kobayashi, Kazuhiro Nishida, MD, PhD, Saori Maegawa, MD, Ryuko Nakayama, MD, Miki Kiyota, MD, Shinsuke Mizutani, MD, Yuji Shimura, MD, PhD, Mio Yamamoto-Sugitani, MD, PhD, Tsutomu Kobayashi, MD, PhD, Yosuke Matsumoto, MD, PhD, Shohei Yokota, MD, PhD, Shigeo Horiike, MD, PhD, Junya Kuroda, MD, PhD, Masafumi Taniwaki, MD, PhD

Blood (2013) 122 (21): 3726.

https://doi.org/10.1182/blood.V122.21.3726.3726

Published: 2013

Journal Articles

RSK2 Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.

Yuji Shimura, MD, Junya Kuroda, MD, PhD, Hisao Nagoshi, MD, Mio Yamamoto-Sugitani, MD, PhD, Tsutomu Kobayashi, MD, PhD, Miki Kiyota, MD, Ryuko Nakayama, MD, Shinsuke Mizutani, MD, Yoshiaki Chinen, MD, Natsumi Sakamoto, Yosuke Matsumoto, MD, PhD, Shigeo Horiike, MD, PhD, Masaki Ri, MD, PhD, Yukimasa Shiotsu, PhD, Shinsuke Iida, MD, PhD, Tomohiko Taki, MD, PhD, Masafumi Taniwaki, MD, PhD

Blood (2012) 120 (21): 2945.

https://doi.org/10.1182/blood.V120.21.2945.2945

Published: 2012

Journal Articles

A Gene-Targeting Approach for the Biological Significance of AML1/Runx1 Arginine-Methylation

Shinsuke Mizutani, MD, Masafumi Taniwaki, MD, PhD, Tsukasa Okuda, MD, PhD

Blood (2012) 120 (21): 1309.

https://doi.org/10.1182/blood.V120.21.1309.1309

Published: 2012

Journal Articles

Fingolimod (FTY720) Overcomes the Resistance to Tyrosine Kinase Inhibitors Via Dual Activation of BIM and BID in Chronic Myelogenous Leukemia

Miki Kiyota, MD, Junya Kuroda, MD, PhD, Mio Yamamoto-Sugitani, MD, PhD, Yuji Shimura, MD, Ryuko Nakayama, MD, Hisao Nagoshi, MD, Shinsuke Mizutani, MD, Yoshiaki Chinen, MD, Natsumi Sakamoto, Tsutomu Kobayashi, MD, PhD, Yosuke Matsumoto, MD, PhD, Shigeo Horiike, MD, PhD, Tomohiko Taki, MD, PhD, Masafumi Taniwaki, MD, PhD

Blood (2012) 120 (21): 3744.

https://doi.org/10.1182/blood.V120.21.3744.3744

Published: 2012

Journal Articles

Biological Analysis of AML1/RUNX1 Arginine-Mutants by Means of Hematopoietic Rescue Experiments of Runx1- deficient Mouse Embryonic Stem Cells,

Shinsuke Mizutani, MD, Masafumi Taniwaki, MD, PhD, Tsukasa Okuda, MD, PhD

Blood (2011) 118 (21): 3382.

https://doi.org/10.1182/blood.V118.21.3382.3382

Published: 2011

NARROW

The Anti-Myeloma Efficacy of TAS0612, a Triple Inhibitor of RSK, AKT, and S6K, and Itssynergistic Combination with Venetoclax in Multiple Myeloma Irrespective of Cytogeneticabnormalities

The Activation Status of RSK2, but Not PDPK1 and AKT, Associates with the Prognosis of Diffuse Large B Cell Lymphoma

TAS0612, a Triple Inhibitor for RSK, AKT, and S6K, Is a Promising Anti-Myeloma Agent Regardless of Types of Cytogenetic/Genetic Abnormality

The Universal Antitumor Activity of TAS0612, a Triple Inhibitor for RSK, AKT, and S6K, in B-Cell Lymphomas Regardless of Disease Subtype

Mir-106a-5p and Mir-146a-5p Delivered By Tumor-Derived Exosomes Promote the Induction of Myeloid-Derived Suppressor Cells from Normal Peripheral Blood Mononuclear Cells in Multiple Myeloma

Nutritional and Cytogenetic Assessment Predicts Favorable Response to Azacitidine Monotherapy for Myelodysplastic Syndromes

More Somatic Mutations Including Those in the Aid-Motif with High-Risk, Histologically Non-Transformed Follicular Lymphomas

3-Phosphoinositide-Dependent Protein Kinase 1 (PDPK1) Is a Pivotal Cell Signaling Mediator in Multiple Myeloma

Novel Fusion Transcripts PVT1-NSMCE2 and BF104016-NSMCE2 Resulting In Depletion Of NSMCE2 Protein In Acute Myeloid Leukemia Harboring 8q24 Amplicons

RSK2 Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.

A Gene-Targeting Approach for the Biological Significance of AML1/Runx1 Arginine-Methylation

Fingolimod (FTY720) Overcomes the Resistance to Tyrosine Kinase Inhibitors Via Dual Activation of BIM and BID in Chronic Myelogenous Leukemia

Biological Analysis of AML1/RUNX1 Arginine-Mutants by Means of Hematopoietic Rescue Experiments of Runx1- deficient Mouse Embryonic Stem Cells,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only